RSS

Lonza

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Integrated solutions provider — Lonza — has announced the launch of a new bioscience website, designed to support the work of scientists across the bioresearch, drug discovery and pharmaceutical manufacturing fields. more

Technology

A Master Service Agreement has been entered by TxCell and Lonza Pharma & Biotech for the manufacture of a CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation. more

News

A long-term contract extension has been agreed by Proteon Therapeutics and Lonza Pharma & Biotech for the commercial supply of the investigational vonapanitase’s active pharmaceutical ingredient (API). more

News

Lonza Pharma & Biotech has invested in a new phase of development at its Portsmouth, New Hampshire, USA site, which will include mid-scale mammalian capacity and the addition of new cell-therapy suites. more

News

Integrated solutions provider, Lonza, has opened a dedicated cell-and-gene-therapy facility with the capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Lonza and BioWa have entered into a licensing agreement with Tillotts Pharma for the POTELLIGENT CHOK1SV Cell Line Technology to be used in research and development of the proprietary antibody TP10. more

Technology

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Supplier to the pharma, biotech and specialty ingredients markets, Lonza, has expanded its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in the US. more

Technology

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Integrated solutions provider, Lonza, has announced it will be establishing centres of excellence for cell and gene therapy to support and accelerate its growth in this area. more

News

With festivities and holidays galore during the latter part of December we thought it would be a good idea to briefly run through some of the pharma news that came out in the run up to Christmas. more

News

Lonza and Massachusetts Eye and Ear (MEE) have granted Akouos (a new biotechnology company) licences for exclusive rights to the ancestral adeno-associated viral vectors (Anc-AAV) gene therapy platform for all hearing and balance disorders. more

News

Capsugel, now a Lonza company, has expanded the clinical trial capabilities, as well as increased development and manufacturing capabilities for specialised drug products using liquid-filled hard capsule (LFHC) technology, at its Edinburgh facility. more

News

Lonza has formed a new research and development (R&D) collaborative innovation centre in Israel, which is set to begin operations at the end of the year. more

News

Lonza, chemical and biological manufacturer, has signed a long-term commercial supply agreement with a biopharmaceutical company, Portola Pharmaceuticals, to secure the supply of AndexXa (andexanet alfa). more

News

Lonza Pharma & Biotech has launched a new concept in biological manufacturing and development, Ibex Solutions. more

Technology

Lonza has announced that, following receipt of all required regulatory approvals, it has completed its acquisition of Capsugel for $5.5 billion in cash, including refinancing of existing Capsugel debt of $2 billion. more

News

Lonza has revealed it has gained all regulatory approvals for its proposed acquisition of Capsugel, which the company anticipates will close over the next few days subject to the satisfaction of customary closing conditions. more

News